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Abstract
Inherited disorders of hyperbilirubinemia may be caused by increased bilirubin production or 
decreased bilirubin clearance. Reduced hepatic bilirubin clearance can be due to defective 1) 
unconjugated bilirubin uptake and intrahepatic storage, 2) conjugation of glucuronic acid to 
bilirubin (e.g. Gilbert syndrome, Crigler-Najjar syndrome, Lucey-Driscoll syndrome, breast milk 
jaundice), 3) bilirubin excretion into bile (Dubin-Johnson syndrome), or 4) conjugated bilirubin re-
uptake (Rotor syndrome). In this review, the molecular mechanisms and clinical manifestations of 
these conditions are described, as well as current approaches to diagnosis and therapy.
Introduction
Bilirubin is the end product of heme catabolism and originates primarily from the 
breakdown of erythrocyte hemoglobin in the reticuloendothelial system. A smaller, yet 
significant proportion is derived from the breakdown of other heme proteins and ineffective 
erythropoiesis in the bone marrow (1). Bilirubin is poorly soluble in water and when 
circulating in blood, is mostly bound to serum albumin. Small amounts of unbound, 
unconjugated bilirubin exist in equilibrium with bound, unconjugated bilirubin in the 
circulation. This unbound, circulating bilirubin is neurotoxic and associated with acute 
bilirubin encephalopathy, which can progress to the more permanent and devastating chronic 
bilirubin encephalopathy, also known as kernicterus (2). Under normal conditions, 
unconjugated bilirubin is rapidly and selectively taken up by hepatocytes, conjugated to 
water-soluble bilirubin glucuronide conjugates, and ultimately secreted into bile.
Disorders that produce hyperbilirubinemia can be divided into those in which excessive 
bilirubin is produced (hemolysis), those in which there is decreased clearance of bilirubin 
(hepatic or intestinal), and combinations of the two. Newborns are particularly susceptible to 
developing hyperbilirubinemia as they have increased bilirubin synthesis (secondary to 
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elevated hemoglobin concentrations and shorter red blood cell lifespan) and inefficient 
hepatic uptake, conjugation, and excretion of bilirubin. The aim of this review is to describe 
hepatic clearance of bilirubin and focus on inherited disorders of hepatic uptake, 
conjugation, and excretion of bilirubin.
Bilirubin Clearance by the Liver
There are four major steps in hepatic clearance of bilirubin: 1) uptake and storage of 
unconjugated bilirubin by hepatocytes, 2) conjugation of bilirubin to bilirubin glucuronides, 
3) excretion of conjugated bilirubin into bile, and 4) reuptake of conjugated bilirubin by 
hepatocytes.
Uptake and Intrahepatic Storage
Bilirubin dissociates from albumin before entering hepatocytes. It is not clear whether the 
initial uptake of free bilirubin is carrier-mediated or by passive diffusion (3). Recent studies 
have described a role for membrane-associated organic anion transport proteins (OATPs) in 
bilirubin uptake by hepatocytes. OATPs belong to the OATP superfamily, which is also 
known as the solute carrier organic anion transporter (SLCO) superfamily (4). Bilirubin is a 
known substrate for the human SLCO1B1/OATP1B1 and SLCO1B3/OATP1B3 proteins (5), 
but most studies have shown that it is conjugated (as opposed to unconjugated) bilirubin that 
is the major substrate for these transporters (5,6). OATPs therefore play an important role in 
the reuptake of conjugated bilirubin (see Secretion into Plasma and Reuptake and Rotor 
Syndrome). However, there is evidence from genome-wide association studies that 
polymorphisms resulting in decreased SLCO1B1/OATP1B1 or SLCO1B3/OATP1B3 
activity are associated with higher serum levels of both conjugated and unconjugated 
bilirubin (7,8), suggesting a role for OATPs in the initial uptake of unconjugated bilirubin 
into hepatocytes as well.
Once inside the hepatocyte, bilirubin binds to the cytoplasmic transport protein ligandin, 
which belongs to the glutathione-S-transferases (GST) family. Ligandin has a much higher 
affinity for bilirubin than albumin, and therefore facilitates intrahepatocyte bilirubin 
accumulation and storage (9).
Conjugation
After binding to ligandin, bilirubin is transported to the smooth endoplasmic reticulum, the 
site at which the conjugating enzyme, uridine diphosphate glucuronosyl transferase 1A1 
(UGT1A1) is localized. UGT1A1 is a transmembrane protein that has a binding site for 
bilirubin and another one for uridine diphosphate glucuronic acid. Conjugation is a two-step 
process; in the first step, the UGT1A1 enzyme catalyzes the transfer of one glucuronic acid 
molecule to one of the carboxyl groups on bilirubin forming bilirubin monoglucuronide. 
Addition of another molecule of glucuronic acid to the second carboxyl group forms 
bilirubin diglucuronide. Both bilirubin mono- and diglucuronide are water-soluble and can 
readily be excreted in bile.
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Excretion into Bile
Once bilirubin glucuronide leaves the endoplasmic reticulum and is transported into the 
cytoplasm, it can diffuse toward either the apical surface of the hepatocyte (canalicular 
surface) or the basolateral surface (sinusoidal surface). At the canalicular surface, it is 
efficiently secreted into bile via ATP-binding cassette (ABC) transporters. The predominant 
ABC transporter responsible for bilirubin excretion is the multidrug resistance-associated 
protein ABCC2/MRP2 transporter (10). Recently, another ABC transporter, the breast 
cancer resistance protein ABCG2/BCRP has also been identified to play a role in bilirubin 
excretion, albeit to a lesser degree (11).
Secretion into Plasma and Reuptake
Interestingly, a substantial fraction of bilirubin glucuronide is secreted back into sinusoidal 
blood and subsequently taken up again by the hepatocytes for biliary excretion. The process 
of conjugated bilirubin excretion at the basolateral surface is mediated by the transporter 
ABCC3/MRP3 and reuptake is via the SLCO1B1/OATP1B1 and SLCO1B3/OATP1B3 
carriers (12). Since the expression of OATP1B1 and OATP1B3 is higher in downstream 
hepatocytes (hepatocytes located near the central vein), it is postulated that this reuptake 
protects upstream hepatocytes (those located near the portal tracts) from saturating their 
biliary secretory capacity (9,13).
Figure 1 summarizes the transporters and enzymes involved in hepatic uptake, conjugation, 
secretion, and reuptake of bilirubin
Developmental Regulation of Transporters and Enzymes Involved in Bilirubin Clearance
All components of hepatic clearance of bilirubin are developmentally regulated and 
newborns have significantly reduced expression and/or activity of the transporters and 
enzymes involved in uptake, conjugation, and excretion of bilirubin. SLCO1B1/OATP1B1 
and SLCO1B3/OATP1B3 mRNA expression is approximately 500-fold lower in neonates 
and 100-fold lower in infants up to the 12 months of age than in adults (14). GST has 
multiple classes, with proteins belonging to class alpha (GST-A) having the highest affinity 
to bilirubin (15). GST-A protein expression is 1.5 to 4-fold lower in newborns and reach 
adult levels after the first 1–2 years of life (16). UGT1A1 enzyme activity is absent from 
fetal livers, and is triggered in newborns by parturition (17). However, newborn UGT1A1 
enzyme activity remains less than 1% of adult activity, and does not reach adult activity until 
3 months of age (18). Hepatic ABCC2/MRP2 mRNA expression is 200-fold lower in 
neonates and 100-fold lower in infants up to 12 months of age than in adults (14). Given the 
reduced ability of the liver for bilirubin uptake, conjugation, and excretion, newborns are 
particularly susceptible to developing hyperbilirubinemia, which can improve as enzyme 
activities and liver function mature.
Inherited Disorders of Bilirubin Clearance
Inherited disorders involving defects in each of the four steps of hepatic bilirubin clearance 
have been described. Many of these disorders present in the newborn period and range in 
presentation from clinically insignificant to neurologically devastating and lethal.
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Disorders of Uptake and Intrahepatic Storage
Disorders of bilirubin uptake and intrahepatic storage are only infrequently described in the 
literature (19), and the clinical significance of these disorders remains to be confirmed. 
Recent studies have demonstrated polymorphisms in GST genes that are associated with 
increased risk of neonatal hyperbilirubinemia (15,20). The most important polymorphism 
associated with neonatal hyperbilirubinemia is one that encodes for a partial gene deletion in 
the GST mu (GST-M) gene class. This GSTM1 null mutation results in complete absence of 
GSTM1 enzyme activity. Also, as noted above, polymorphisms in SLCO1B1/OATP1B1 and 
SLCO1B3/OATP1B3 may modestly contribute to unconjugated hyperbilirubinemia (7,8).
Disorders of Conjugation
Inherited disorders of conjugation are primarily due to alterations in the UGT1A1 gene, 
resulting in decreased or absent enzyme expression and function.
UGT Gene—The UGT gene is a superfamily of genes that encode enzymes catalyzing 
glucuronidation of various substrates to facilitate their excretion (21). The gene that governs 
bilirubin conjugation, UGT1 was cloned by Ritter et al in 1991 (22) and is located on 
chromosome 2, at 2q37 (23). This gene consists of four common exons (exons 2, 3, 4, and 5) 
and 13 unique promoter and first exons (variable exons) (Figure 2). A single variable first 
exon and its promoter are spliced to the four common exons prior to transcription. Of the 13 
possible genes that can be encoded, only that containing the variable exon A1 is involved in 
bilirubin conjugation (13).
UGT1A1 is the only enzyme catalyzing the generation of water-soluble bilirubin 
glucuronides in hepatocytes, thus mutations in this gene lead to deficiencies in bilirubin 
conjugation and excretion. To date, 130 UGT1A1 mutations, in both coding and non-coding 
regions of the gene, have been identified that decrease or abrogate enzymatic function (24). 
Conversely, UGT1A1 activity can be increased by phenobarbital administration, which 
induces UGT1A1 gene expression by activating the distal phenobarbital response enhancer 
element (25).
Gilbert syndrome (GS)—First described in 1901 by Gilbert and Lereboulet (26), GS is 
the most common hereditary hyperbilirubinemia syndrome, occurring in 3–13% of the 
population (27,28). It is typically associated with at least 50% decrease in hepatic bilirubin 
UGT activity (29). GS is now regarded as an autosomal recessive disorder, with affected 
patients being either homozygotes or compound heterozygotes (i.e. two different recessive 
alleles at a particular locus) (30). More than 100 different mutations have been implicated in 
GS and their frequencies differ among different ethnic groups (31). The most common 
genotype among Caucasians with GS is the homozygous polymorphism of two extra bases 
(TA) in the TATAA box sequence of the promoter region of the UGT1A1 gene, resulting in a 
sequence of A(TA)7TAA (also known as UGT1A1*28) instead of the normal 
A(TA)6TAA(32,33). The extra TA repeat lessens the affinity of TATAA-binding protein to 
the TATAA box, resulting in decreased gene expression. This A(TA)7TAA variant is highly 
prevalent in the Western population, with an allelic frequency of 0.4 ((30,34). Various other 
mutations, including missense mutations in the coding region are more prevalent in non-
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Western populations. For example, in East Asians from Japan, Korea, and China, GS most 
commonly results from the Gly71Arg mutation (G71R; UGT1A1*6) in exon 1 (35). The 
allelic frequency of the G71R mutation in this population is 0.16–0.21 (36,37), whereas the 
A(TA)7TAA allelic frequency is only 0.11–0.15 (36).
Clinical manifestation: Although GS is an inherited disorder, it typically first presents as 
mild, intermittent unconjugated hyperbilirubinemia in otherwise asymptomatic young adults 
without evidence of hemolysis or liver injury. GS can present in the newborn period, 
especially if there is concurrent hemolytic disease such as ABO incompatibility or 
glucose-6-phophatate dehydrogenase (G6PD) deficiency (38). Such infants are at high risk 
for developing severe hyperbilirubinemia and even kernicterus. GS can also contribute to 
neonatal hyperbilirubinemia in the absence of hemolytic disease as several authors have 
shown that the A(TA)7TAA homozygous genotype is associated with higher serum bilirubin 
levels, when compared to heterozygous and wild type controls (39–41). However, the 
clinical significance of this finding remains unclear as the infants in these studies had either 
subclinical or only mild/moderate hyperbilirubinemia (27). GS has also been associated with 
the jaundice of inadequate breastfeeding with weight loss (“breastfeeding jaundice”) (42,43) 
and with breast milk jaundice (see Breast milk jaundice) (44,45).
Diagnosis and management: In older children and adults, the diagnosis of GS can be made 
by administering intravenous nicotinic acid (niacin) or oral rifampin and monitoring the 
subsequent rise in bilirubin concentrations (46). Liver biopsy is not indicated and is usually 
normal. Genetic testing can be useful in the work-up of prolonged neonatal jaundice, with 
genotyping of the A(TA)7TAA variant in non-Asians and Gly71Arg mutation analysis in 
Asian patients.
Crigler-Najjar syndrome type I (CN syndrome type I)—In 1952, Crigler and Najjar 
(47) described the most lethal form of hereditary hyperbilirubinemia, CN syndrome type I, 
which is characterized by absent or nearly absent UGT1A1 enzyme activity (48). CN 
syndromes are inherited in an autosomal recessive manner and patients are homozygotes or 
compound heterozygotes. Mutations in CN syndrome type I are deleterious and consist of 
either premature truncation or deletion of key amino acid sequences on any of the five exons 
of the UGT1A1 gene (24). Additionally, intronic mutations resulting in frameshifts and 
premature stop codons have been described (49). The majority of the mutations found in CN 
syndrome type I are found in the common exons 2–5 and thus affect many UGT1 enzymes 
(50).
Clinical manifestation: CN syndrome type I presents shortly after birth with serum 
bilirubin levels greater than 20 to 50 mg/dL. Consequently, it is associated with bilirubin 
encephalopathy and death unless managed by aggressive phototherapy and exchange 
transfusions in the immediate newborn period (51). The risk for kernicterus persists into 
adult life (52).
Diagnosis and management: There is currently no simple test to confirm the diagnosis of 
CN syndrome type I. Definitive diagnosis is by gene analysis and sequencing the coding 
region for known mutations. Management in the newborn period consists of aggressive 
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phototherapy and exchange transfusions to keep bilirubin levels below the threshold for 
kernicterus. Phototherapy for 8–12 hours daily is continued throughout the early years of 
life, though its effectiveness decreases with time (53). The nonsense or stop codons that 
cause CN syndrome type I preclude the use of phenobarbital to upregulate gene expression 
(54). Liver transplantation remains the only definitive treatment for this disease (55). Gene 
therapy may be a promising therapeutic option for these patients in the near future (56).
Crigler-Najjar syndrome type II (CN syndrome type II, aka Arias syndrome)—
Described by Arias in 1962 (57), CN syndrome type II is characterized by reduced (but not 
abolished) UGT1A1 enzyme activity (< 10% of normal) (58). Unlike CN syndrome type I, 
which is caused by various types of deleterious mutations, the genetic defect in CN 
syndrome type II is usually a point mutation, causing a substitution of a single amino acid 
residue, thereby reducing but not eliminating enzyme activity (24).
Clinical manifestation: Unconjugated hyperbilirubinemia occurs in the first days of life, 
but total bilirubin levels usually do not exceed 20 mg/dL (51). CN syndrome type II rarely 
results in kernicterus. In older children and adults, illness and stress may cause temporary 
increases in bilirubin levels.
Diagnosis and management: CN syndrome type II can be clinically distinguished from CN 
syndrome type I by lower levels of bilirubin (usually less than 20 mg/dL) and a decrease in 
serum bilirubin levels by more than 30% after treatment with phenobarbital (58). Analysis of 
bile pigments for bilirubin conjugates can also differentiate the two CN syndromes, with 
only trace amounts of conjugated bilirubin present in type I and significant amounts of 
monoconjugated bilirubin present in type II (59). Treatment includes aggressive 
phototherapy in the newborn period and occasionally phenobarbital therapy. These patients 
generally have a good prognosis.
Are GS and CN syndrome type I ends of a continuous spectrum?—Historically 
GS, CN syndrome type I, and CN syndrome type II have been characterized as distinct 
clinical syndromes, distinguished by the degree of unconjugated hyperbilirubinemia. 
However, intermediate phenotypes have been well described, suggesting that there is a 
continuous spectrum of altered bilirubin conjugation (60,61). Due to the high frequency of 
the Gilbert-type promoter in the general population (up to 40% of the Western population 
has at least one Gilbert type allele), heterozygous carriers of mutations that cause CN 
syndromes can also carry the Gilbert-type promoter on their normal allele, resulting in 
compound heterozygosity and intermediate levels of hyperbilirubinemia. Therefore, the 
variability of the UGT1A1 gene locus most likely leads to a continuous spectrum of altered 
bilirubin conjugation, with GS and CN syndrome type 1 representing the two ends of the 
spectrum (31).
Lucey-Driscoll syndrome (aka Transient Familial Neonatal Hyperbilirubinemia)
—In 1960, Lucey et al. (62) described a rare familial disorder that caused severe 
unconjugated hyperbilirubinemia is the first few days of life. In vitro testing demonstrated 
that sera of affected infants and their mothers contained an unidentified inhibitor of 
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UGT1A1 activity. Since its original description in 1960, additional cases of Lucey-Driscoll 
syndrome have not been reported in the literature and its existence has been questioned.
Clinical manifestation: Based on the original description, this syndrome presents with 
severe hyperbilirubinemia in the immediate newborn period and can result in kernicterus and 
death. Children who survive the neonatal period have no recurrence of hyperbilirubinemia 
(62).
Diagnosis and management: The serum inhibitory effects gradually decline after delivery 
and therefore this is a self-resolving condition. However, given the risk of severe 
hyperbilirubinemia, these infants need to be monitored closely in the first two weeks of life 
and may need treatment with aggressive phototherapy and possibly exchange transfusion if 
threshold bilirubin levels are reached.
Breast milk jaundice—First described by Newman and Gross in 1963 (63), breast milk 
jaundice refers to a common and relatively benign cause of unconjugated hyperbilirubinemia 
in healthy newborns who are primarily breastfed. Its etiology remains unknown, and several 
components of breast milk such as pregnane-3β,20α-diol (pregnanediol) (64), other steroids 
(cortisol and estriol), nonesterified fatty acids (65), β-glucoronidase (66), and epidermal 
growth factor (67) have been implicated in its pathogenesis. Interestingly, polymorphic 
mutations of UGT1A1 (especially mutations seen in GS) are associated with breast milk 
jaundice. Specifically, studies in East Asian infants have shown a causal relationship 
between infants with breast milk jaundice and the G71R mutation (36,45). A recent in vitro 
study using transfected HepG2 cells demonstrated that pregnanediol did not alter UGT1A1 
transcriptional and enzyme activity in wild-type or A(TA)7TAA variant expression vectors, 
but reduced enzyme activity in G71R variant vectors by 51% (68). These studies suggest 
that breast milk jaundice is caused by a combination of genetic and environmental factors 
(i.e. breast milk components).
Clinical manifestations: Breast milk jaundice develops after 4–7 days of life and can 
persist for as long as 3–4 months before spontaneous resolution. It is distinguished from 
“breastfeeding jaundice”, which occurs with mild dehydration and weight loss in the first 
few days of life because of insufficient intake or production of breast milk. Infants with 
breast milk jaundice are otherwise healthy, with normal weight gain, normal stool and urine 
output, and a normal physical examination. Total serum bilirubin levels usually do not 
exceed 12 mg/dL (69), though higher bilirubin levels and rare cases of kernicterus have been 
reported (70).
Diagnosis and management: Discontinuation of breast milk and substitution with formula 
results in rapid improvement in hyperbilirubinemia, which is both a diagnostic and 
therapeutic option for breast milk jaundice. However, since breast milk jaundice is a benign 
and self-limiting condition, current recommendations do not support discontinuation of 
breastfeeding in these infants (69).
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Disorders of Excretion into Bile
Dubin-Johnson syndrome (DJS)—DJS was first described in 1954 by Dubin et al and 
Sprinz et al who reported several cases of healthy young adults with chronic low-grade 
jaundice (mostly conjugated hyperbilirubinemia) and black livers, with no other features of 
hepatobiliary disease (71,72). It is an autosomal recessive disorder and genomic studies have 
shown that DJS results from homozygous or compound heterozygous mutations in ABCC2/
MRP2 resulting in either absent or deficient expression of this transporter (73). Several 
different mutations have been described in DJS patients, including exon skipping, missense, 
nonsense and base deletion. Most mutations result in stop codons and failure of MRP2 
transcription. Less frequently, they can result in endoplasmic reticulum retention of MRP2 
and failure of translocation to the canalicular membrane (9).
Clinical manifestation: DJS usually presents in young adulthood with predominantly 
conjugated hyperbilirubinemia and otherwise normal liver studies. The conjugated 
hyperbilirubinemia is mild because of urinary excretion of bilirubin glucuronides. Most 
patients are asymptomatic except for occasional abdominal pain (13). There is no risk of 
fibrosis or cirrhosis. Rarely, DJS can present in the neonatal period. Neonatal DJS differs 
from adult-onset DJS in that it presents with severe cholestasis and hepatomegaly. Bilirubin 
levels can reach > 20 mg/dL. Increased severity in neonates has been attributed to immature 
bile physiology combined with the MRP2 defect. As the liver matures, infants become 
asymptomatic until later in life, when they can present with intermittent hyperbilirubinemia 
(74).
Diagnosis and management: DJS in a benign disease and in adolescents and adults it does 
not require treatment. Diagnosis, however, is important to eliminate the possibility of other 
hepatobiliary disorders that may lead to hepatic injury. In addition to elevated conjugated 
bilirubin levels in the setting of normal liver function tests, urine tests are diagnostic. Urine 
tests reveal normal total coproporphyrin levels but the characterization of the coproporphyrin 
reveals 80% coproporphyrin I in affected individuals, compared to 75% coproporphyrin III 
in healthy controls (31). Coproporphyrin I is a metabolic byproduct of heme synthesis and 
also an endogenous substrate of MRP2; therefore serum and urinary levels are increased in 
the presence of defective MRP2 (73). Hepatobiliary iminodiacetic acid (HIDA) scan will 
show either normal or slightly delayed visualization of the liver, with absent or delayed 
gallbladder filling (75). Liver histology, though not necessary in establishing the diagnosis, 
characteristically shows the presence of dark lysosomal melanin-like pigment deposits (12). 
Genotyping of ABCC2 gene is possible, but typically not part of the routine clinical work up 
(31).
DJS should be suspected in any neonate with unexplained prolonged moderate to severe 
conjugated hyperbilirubinemia. Similar to adults, diagnosis is made by elevated urine 
coproporphyrin I levels. Computerized tomography (CT) of the abdomen can also be done 
and will show attenuation of the liver (75). Therefore, characterization of urinary 
coproporphyrins and abdominal CT should confirm the diagnosis without additional invasive 
means. Given the significant cholestasis that occurs in this age group, treatment with 
phenobarbital and ursodeoxycholic acid is recommended (74).
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Disorders of Reuptake
Rotor syndrome (RS)—RS was first described by Rotor et al in 1948 and was initially 
considered a variant of DJS (76). Subsequently, a number of functional studies confirmed 
that patients with RS do not have defective biliary excretion, but rather a defect in hepatic 
uptake and storage. RS is an autosomal recessive disorder. Animal experiments and studies 
of patients with RS suggest that there are homozygous mutations of both SLCO1B1/
OATP1B1 and SLCO1B3/OATP1B3 resulting in simultaneous absence of OATP1B1 and 
OATP1B3 transporters (12). Of note, SLCO1B1 and SLCO1B3 lie very close together on 
chromosome 12.
Clinical manifestation: Clinically, the disorder is indistinguishable from DJS, and presents 
with predominantly a mixed conjugated and unconjugated hyperbilirubinemia in otherwise 
asymptomatic individuals. It can present in the neonatal period or in childhood. Serum total 
bilirubin levels are usually between 2 and 5 mg/dL, but can be higher.
Diagnosis and management: RS is benign and does not require any therapy. Again, 
diagnosis is important to differentiate from other causes of hepatobiliary disorders. Urine 
tests are diagnostic and can differentiate RS from DJS. In RS, total coproporphyrin excretion 
in urine is elevated 2–5 fold, with 65% constituting coproporphyrin I (31). Further 
diagnostic or invasive testing is usually not indicated. If performed, a HIDA scan will reveal 
slow liver uptake and prominent kidney excretion (12) and histology will show normal liver 
tissue with absent pigment (9).
The main characteristics of these disorders are summarized in Table 1 and the defective 
transporters/enzymes are shown in Figure 3.
Summary
Inherited disorders of bilirubin clearance can present with either unconjugated or conjugated 
hyperbilirubinemia in the newborn period. Understanding the molecular basis and clinical 
presentation of these syndromes is critical for differentiating those that are benign from 
those that can be lethal and associated with kernicterus.
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Figure 1. 
Schematic view of transporters and enzymes involved in hepatic bilirubin clearance. (Alb, 
albumin; BCRP, breast cancer resistance protein; BMG, bilirubin monoglucuronide; BDG, 
bilirubin diglucuronide; GST, glutathione-S-transferase; MRP, multidrug resistance-
associated protein; OATP, organic anion transport protein; UCB, unconjugated bilirubin; 
UGT, uridine diphosphate glucuronosyl transferase).
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Figure 2. 
Schematic representation of the UGT1 gene locus and the UGT1A1 protein. (Chr, 
chromosome; PR, promoter regions; UGT, uridine diphosphate glucuronosyl transferase).
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Figure 3. 
Schematic view of transporters and enzymes involved in inherited disorders of bilirubin 
clearance. (Alb, albumin; BCRP, breast cancer resistance protein; BMG, bilirubin 
monoglucuronide; BDG, bilirubin diglucuronide; CN, Crigler-Najjar; DJS, Dubin-Johnson 
syndrome; GS, Gilbert syndrome; GST, glutathione-S-transferase; MRP, multidrug 
resistance-associated protein; OATP, organic anion transport protein; RS, Rotor syndrome; 
UCB, unconjugated bilirubin; UGT, uridine diphosphate glucuronosyl transferase).
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